Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04130997 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 83 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. New version filed on ClinicalTrials.gov
  2. 7 versions Re-verified since Feb 25, 2026, no change to tracked fieldsv76-v82
  3. Primary and study completion dates: Feb 1, 2030 to May 31, 2032v75
  4. 12 versions Re-verified since Feb 27, 2025, no change to tracked fieldsv63-v74
  5. Primary and study completion dates: Apr 1, 2027 to Feb 1, 2030v62
Show 28 earlier versionsHide 28 earlier versions
  1. 9 versions Re-verified since Apr 15, 2024, no change to tracked fieldsv53-v61
  2. Trial status: Enrolling by Invitation to Active, Not Recruiting Primary and study completion dates: Apr 2027 to Apr 1, 2027v52 Show 1 more changeShow less
    • Primary and study completion dates: Apr 2027 to Apr 1, 2027
  3. 9 versions Re-verified since May 31, 2023, no change to tracked fieldsv43-v51
  4. Study sites: 85 to 86v42
  5. Re-verified, no change to tracked fieldsv41
  6. Primary and study completion dates: Oct 2023 to Apr 2027 Enrollment target: 900 to 1100v40 Show 1 more changeShow less
    • Enrollment target: 900 to 1100
  7. 6 versions Re-verified since Jul 20, 2022, no change to tracked fieldsv34-v39
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
Trial Details
NCT Number NCT04130997
Lead Sponsor TG Therapeutics, Inc.
Conditions Relapsing Multiple Sclerosis (RMS)
Enrollment 1,100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov